Discovery of new anti-tuberculosis (TB) drugs is a time-consuming process due to the slow-growing nature of Mycobacterium tuberculosis (Mtb). A requirement of biosafety level 3 (BSL-3) facility for performing research associated with Mtb is another limitation for the development of TB drug discovery. In our screening of BSL-1 Mycobacterium spp. against a battery of TB drugs, M. smegmatis (ATCC607) exhibits good agreement with its drug susceptibility against the TB drugs under a low-nutrient culture medium (0.5% Tween 80 in Middlebrook 7H9 broth). M. smegmatis (ATCC607) enters its dormant form in 14 days under a nutrient-deficient condition (a PBS buffer), and shows resistance to a majority of TB drugs, but shows susceptibility to amikacin, capreomycin, ethambutol, and rifampicin (with high concentrations) whose activities against non-replicating (or dormant) Mtb were previously validated.

由于结核分枝杆菌（Mtb）的缓慢生长特性，发现新的抗结核（TB）药物是一个耗时的过程。进行与Mtb相关的研究的生物安全3级（BSL-3）设施要求是开发结核病药物发现的另一个限制。在我们对BSL-1分枝杆菌属的筛选中。对于一系列结核病药物，耻垢分枝杆菌（ATCC607）在低营养培养基（Middlebrook 7H9肉汤中含0.5％Tween 80）下对结核病药物的敏感性高。耻垢分枝杆菌 （ATCC607）在缺乏营养的条件下（PBS缓冲液）在14天内进入休眠状态，对大多数TB药物显示耐药性，但对阿米卡星，卡普霉素，乙胺丁醇和利福平（高浓度）敏感先前已验证了针对非复制（或休眠）Mtb的活性。